EFESA
Live / Registered — Registered (as of 04 Mar 2025)
What this means for you
Registered since 04 Mar 2025. The owner can stop confusingly similar uses in the classes it covers.
Record
- Serial number
- 79391354
- Registration number
- 7709057
- Mark type
- Word mark
- Filed
- 22 Dec 2023
- Published for opposition
- 14 Jan 2025
- Registered
- 04 Mar 2025
- Attorney of record
- Patricia A Wilczynski Brozek
Goods and services
- Class 005 — Pharmaceuticals: Pharmaceutical preparations for the treatment of diseases of the endocrine system; pharmaceutical agents affecting metabolism; cardiovascular treatment preparations; cardiovascular pharmaceutical preparations; pharmaceutical preparations for the treatment of kidney disorders; pharmaceutical preparations for the treatment of kidney diseases; pharmaceutical preparations for the treatment of diseases of the metabolic system; pharmaceutical preparations for the treatment of cardiovascular disease; medicines for the treatment of cardiovascular and cerebrovascular diseases; pills for dizziness symptoms treatment being pharmaceutical preparations for the treatment of dizziness; biological preparations for medical purposes being biological preparations for the treatment of anemia, kidney disease and kidney disorders; cardiovascular agents for medical purposes; drugs for medical purposes being pharmaceutical preparations for the treatment of anemia, kidney disease and kidney disorders; synthetic peptides for pharmaceutical purposes being synthetic peptides for the treatment of anemia, kidney disease and kidney disorders; pharmaceuticals being pharmaceutical preparations for the treatment of anemia, kidney disease and kidney disorders; medicines for human purposes being pharmaceutical preparations for the treatment of anemia, kidney disease and kidney disorders; anemia treatment medicines that stimulate red blood cell production being pharmaceutical preparations for the treatment of anemia; medicines to stimulate red blood cell production being pharmaceutical preparations for the treatment of anemia; pharmaceutical preparations for treatment of chronic kidney disease and anemia; biological preparations for treatment of anemia; biological preparations to stimulate red blood cell production for veterinary and medical purposes being biological preparations for the treatment of anemia; synthetic peptides for pharmaceutical and anemia treatment purposes being synthetic peptides for the treatment of anemia; synthetic peptides for pharmaceutical and kidney disease treatment purposes being synthetic peptides for the treatment of kidney disease
Owner
- Genexine, Inc., KR
- Genexine, Inc., KR
- Genexine, Inc., KR
Prosecution history
- 10 Oct 2025 — FINAL DECISION TRANSACTION PROCESSED BY IB
- 19 Sept 2025 — FINAL DISPOSITION NOTICE SENT TO IB
- 19 Sept 2025 — FINAL DISPOSITION PROCESSED
- 29 Aug 2025 — NOTIFICATION OF POSSIBLE OPPOSITION - PROCESSED BY IB
- 13 Aug 2025 — NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
- 13 Aug 2025 — NOTIFICATION OF POSSIBLE OPPOSITION CREATED, TO BE SENT TO IB
- 05 Jun 2025 — FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
- 04 Mar 2025 — REGISTERED-PRINCIPAL REGISTER
- 04 Mar 2025 — NOTICE OF REGISTRATION CONFIRMATION EMAILED
- 07 Feb 2025 — NEW REPRESENTATIVE AT IB RECEIVED
- 14 Jan 2025 — OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
- 14 Jan 2025 — PUBLISHED FOR OPPOSITION
- 08 Jan 2025 — NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
- 19 Dec 2024 — APPROVED FOR PUB - PRINCIPAL REGISTER
- 19 Dec 2024 — TEAS/EMAIL CORRESPONDENCE ENTERED